Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension

European Respiratory Journal

Volumn 49, Issue 6, 2017, Pages

  van de Veerdonk, Mariëlle C ^a   Huis in t Veld, Anna E ^a   Marcus, J Tim ^a   Westerhof, Nico ^a   Heymans, Martijn W ^a   Bogaard, Harm Jan ^a   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; MACITENTAN; SILDENAFIL; SITAXSENTAN; TADALAFIL; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PEPTIDE FRAGMENT; PHOSPHODIESTERASE V INHIBITOR; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART RIGHT VENTRICLE VOLUME; HUMAN; INCIDENCE; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NEW YORK HEART ASSOCIATION CLASS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SIX MINUTE WALK TEST; AGED; BLOOD; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL; VASCULAR RESISTANCE;

ADULT; AGED; CARDIAC CATHETERIZATION; DRUG THERAPY, COMBINATION; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NETHERLANDS; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE 5 INHIBITORS; RETROSPECTIVE STUDIES; STROKE VOLUME; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, RIGHT;

EID: 85030775601     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00007-2017     Document Type: Article

References (39)

1. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
2. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
3. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975.
4. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D73-D81.
5. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-844.
6. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
7. Mauritz GJ, Vonk-Noordegraaf A, Kind T, et al. Pulmonary endarterectomy normalizes interventricular dyssynchrony and right ventricular systolic wall stress. J Cardiovasc Magn Reson 2012; 14: 1-9.
8. Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016; 47: 1727-1736.
9. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2511-2519.
10. Vonk Noordegraaf A, Westerhof N. Right ventricular ejection fraction and NT-proBNP are both indicators of wall stress in pulmonary hypertension. Eur Respir J 2007; 29: 622-623.
11. Peacock AJ, Crawley S, McLure L, et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging 2014; 7: 107-114.
12. van Wolferen SA, Boonstra A, Marcus JT, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 2006; 92: 1860-1861.
13. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292-1297.
14. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-1386.
15. Hinderliter AL, Willis PW 4th, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997; 95: 1479-1486.
16. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 2004; 125: 572-579.
17. Katz J, Whang J, Boxt LM, et al. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. J Am Coll Cardiol 1993; 21: 1475-1481.
18. van de Veerdonk MC, Marcus JT, Westerhof N, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015; 147: 1063-1071.
19. Westerhof N, Stergiopulos N, Noble MIM. Snapshots of hemodynamics: an aid for clinical research and graduate education. 2nd Edn. New York, Springer, 2010.
20. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
21. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006; 28: 1190-1194.
22. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
23. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012; 31: 150-158.
24. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
25. Swift AJ, Rajaram S, Campbell MJ, et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2014; 7: 100-106.
26. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-1257.
27. Badagliacca R, Poscia R, Pezzuto B, et al. Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 2016; 35: 1321-1329.
28. Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013; 62: D22-D33.
29. Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1102-1110.
30. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131: 402-409.
31. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645-1650.
32. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007; 29: 737-744.
33. van de Veerdonk MC, Dusoswa SA, Marcus JT, et al. The importance of trabecular hypertrophy in right ventricular adaptation to chronic pressure overload. Int J Cardiovasc Imaging 2014; 30: 357-365.
34. Kawut SM, Barr RG, Lima JA, et al. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)-right ventricle study. Circulation 2012; 126: 1681-1688.
35. Ryo K, Goda A, Onishi T, et al. Characterization of right ventricular remodeling in pulmonary hypertension associated with patient outcomes by 3-dimensional wall motion tracking echocardiography. Circ Cardiovasc Imaging 2015; 8: 1-9.
36. Westerhof N, Boer C, Lamberts RR, et al. Cross-talk between cardiac muscle and coronary vasculature. Physiol Rev 2006; 86: 1263-1308.
37. Gomez A, Bialostozky D, Zajarias A, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 2001; 38: 1137-1142.
38. Vonk-Noordegraaf A, Westerhof N. Describing right ventricular function. Eur Respir J 2013; 41: 1419-1423.
39. Voelkel NF, Gomez-Arroyo J, Abbate A, et al. Mechanisms of right heart failure-a work in progress and a plea for failure prevention. Pulm Circ 2013; 3: 137-143.